Segment Information (Tables)

6 Months Ended

Jun. 30, 2013

Segment Information

Schedule of segment and geographic area information

	Net Sales to External Customers								Operating Earnings
	Three Months				Six Months				Three Months						Six Months
	Ended June 30				Ended June 30				Ended June 30						Ended June 30
(dollars in millions)	2013		2012		2013		2012		2013			2012			2013			2012
Established Pharmaceutical Products	$	1,218	$	1,246	$	2,450	$	2,503	$	258		$	269		$	543		$	562
Nutritional Products	1,704		1,580		3,404		3,142		313			214			655			474
Diagnostic Products	1,135		1,078		2,223		2,120		242			233			503			427
Vascular Products	751		766		1,492		1,569		221			249			408			516
Total Reportable Segments	4,808		4,670		9,569		9,334		1,034			965			2,109			1,979
Other	638		643		1,255		1,263
Net Sales	$	5,446	$	5,313	$	10,824	$	10,597
Corporate functions and benefit plans costs									(127		)	(184		)	(247		)	(343		)
Non-reportable segments									99			105			187			186
Net interest expense									(24		)	(64		)	(49		)	(130		)
Share-based compensation (a)									(52		)	(57		)	(177		)	(185		)
Amortization of intangible assets									(197		)	(195		)	(396		)	(404		)
Other, net (b)									(132		)	(40		)	(272		)	(110		)
Consolidated Earnings from Continuing Operations Before Taxes									$	601		$	530		$	1,155		$	993

(a) Approximately 40 to 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b) Other, net includes the Net foreign exchange loss (gain) in the Condensed Consolidated Statement of Earnings, expenses associated with restructuring programs and other costs.  For the six months ended June 30, 2012, it also includes income from the resolution of a contractual agreement.